The session below was sponsored by Takeda during the ESPID 2025 Meeting and is intended for HCPs only. *Not included in the main event CME/CPD credit.
Dengue in the Pediatric Population: Burden, Management, and Emerging Solutions – Supported by Takeda (MAY 27, 09:00-10:00)
Session Description:
The session addresses the critical issue of dengue, starting with an overview of Qdenga. The program provides a comprehensive understanding of the dengue’s impact by examining the pediatric burden of dengue and prevention/management strategies from both non-endemic and endemic perspectives. A key focus is on the real-world experience of Qdenga in dengue prevention, utilizing data from the Vacunar Network in Argentina. The session concludes with an interactive Q&A session.
Francesca F Norman
(Spain)
MBBS, BMedSci, PhD, FISTM Counsellor, ISTM Executive Board, 2021-2025. Specialist training in Internal Medicine, Master´s degree in Tropical Medicine and International Health.
Kleber Luz
Brazil
Associate Professor IV at the Institute of Tropical Diseases at the Federal University of Rio Grande do Norte
Vanesa Edelvais Castellano
(Argentina)
Medical Doctor specialized in Pediatrics from the University of Buenos Aires (UBA)
Note that this recording is intended for HCPs only.
This promotional symposium has been commissioned and funded by GSK and is for Healthcare Professionals only.
*Not included in the main event CME/CPD credit.
Addressing Challenges & Solutions in Meningococcal Disease Prevention – Supported by GSK (MAY 27, 13:15-14:15)
Session Description:
This promotional symposium initiated and funded by GSK features an unscripted panel discussion with three global experts in Invasive Meningococcal Disease. Hear perspectives from Brazil, Spain, Germany and Switzerland as more countries expand protection to age groups beyond infancy.
This promotional symposium has been commissioned and funded by GSK and is for Healthcare Professionals only.
Link to prescribing information for GSK products mentioned during this symposium can be found below.
EU Prescribing Information: Bexsero Meningococcal group B Vaccine (rDNA, component, adsorbed) – suspension for injection in pre-filled syringe
UK Prescribing Information: Bexsero Meningococcal Group B vaccine (rDNA, component, adsorbed) – suspension for injection in pre-filled syringe (emc)
Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for “MHRA in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline:+44 0800 221 441
For other countries, please access reporting information at Report a possible side effect
Trademarks are owned by or licensed to the GSK group of companies Belgium address: GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2025 GSK group of companies or its licensor
PM-GBL-BEX-WCNT-25001 – September 2025
Teresa Bruce
(USA)
GSK Global Medical Director.
Marco Aurelio Palazzi Safadi
Brazil
Associate Professor of Paediatrics. Head of the Division of Paediatric Infectious Diseases – Santa Casa de Sao Paulo School of Medical Sciences.
Irene Rivero Calle
(Spain)
Consultant in Paediatrics and Paediatric Infectious Diseases at Hospital Clínico Universitario de Santiago de Compostela.
Ulrich Heininger
(Switzerland)
Paediatrician specializing in infectious diseases and vaccinology. University of Basel Children’s Hospital (UKBB).
Note that this recording is intended for HCPs only.
